Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > REGULATORY
REGULATORY
- LDP Loses Big in Snap Election, Many Health-Savvy Members Ousted
October 28, 2024
- MHLW Lists Up 78 Drug-Loss Assets, Asks Makers to Report Any Hurdles in Development
October 28, 2024
- No New Safety Concerns for COVID-19 Vaccines in Japan: Experts
October 28, 2024
- MHLW to Update List of “Stable Supply Medicines” Eyeing Expansion
October 25, 2024
- MHLW Announces Revisions to Conditional Approval Rules
October 25, 2024
- MHLW Outlines Envisaged Cases of Regulatory Submissions without Japanese Data, Covering Rare Disease Drugs
October 24, 2024
- Contribution to Drug Discovery Up for Discussion in Revising Core Hospital Criteria
October 24, 2024
- Marukawa Touts Importance of Drug Innovation in Lower House Campaign
October 24, 2024
- LDP’s Hashimoto Makes Rare Speech on Drug Prices amid Close Race in Okayama
October 22, 2024
- Ex-Health Minister Gets Kostaive Shot, Warns against “Unscientific Concerns”
October 21, 2024
- ITP Pediatric Dosage Approvals on Agenda of MHLW Panel for Oct. 31
October 18, 2024
- MHLW Panel to Review BeiGene’s 1st Drug Candidate in Japan and More on Oct. 30
October 17, 2024
- Multiple Candidates Tout Drug Policies as Snap Poll Campaigning Starts
October 16, 2024
- MHLW to Run Follow-Up Survey on Updated Commercial Guidelines, Solo Distribution
October 15, 2024
- Japan Political Parties Push Varied Pharma Policies as Election Campaign Kicks Off
October 15, 2024
- Japan’s Healthcare Spending Hits 46.7 Trillion Yen in FY2022
October 15, 2024
- MHLW Asks for Ramp Up of HPV Vaccines after 5-Fold Rise in Demand
October 11, 2024
- MHLW Orders Label Revision for Systemic NSAIDs
October 11, 2024
- Xocova to Face CEA Price Cuts on Poor Cost Performance vs. SOC
October 10, 2024
- Kisunla to Follow Same Rules as Leqembi in Pricing and Post-Launch Review
October 10, 2024
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…